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株具有细胞毒活性的曲霉菌 Aspergillus versicolor 作为研究对象。通过对
Aspergillus versicolor进行大规模培养发酵，应用大孔吸附树脂、ODS 柱层析、
硅胶、制备 HPLC 等分离技术，对其次生代谢产物进行分离，得到 22个化合物，
并根据化合物的理化性质、核磁共振谱 (1H-NMR, 13C-NMR)及与文献报道对比
鉴定了其化合物结构，分别为：苯甲酸正丁酯 (1)，麦角甾醇 (2)，角甾-6,22-
二烯-3,5,8-三醇 (3)，环-(异亮氨酸-缬氨酸) (4)，环-(脯氨酸-缬氨酸) (5)，对羟
基苯乙醇 (6)，对羟基苯甲酸 (7)，3-羟基苯甲酸 (8)，7,7-二(3-吲哚基)对甲酚
(9)，3,3-二(1H-3-吲哚基)-2-吲哚酮 (10)，黑麦酮酸 F (11)，环-(脯氨酸-酪氨酸)
(12)，环-(苯丙氨酸-脯氨酸) (13)，环-(丙氨酸-异亮氨酸) (14)，环-(丙氨酸-亮氨
酸) (15)，氯霉素水解物 (16)，环-(色氨酸-酪氨酸) (17)，环-(苯丙氨酸-酪氨酸)
(18)，腺嘌呤核苷 (19)，5-硝基吲哚-2-羧酸乙酯 (20)，7-苄氧基吲哚 (21)，1,1,2-





















In recent years, with the constant research on the marine ecosystem, Marine
microorganisms－a new object of study about anticancer drug is gradually coming
into sight. Marine microorganisms are widely distributed and have a great quantity,
its natural products put up a great extensive bioactivities, such as anti-tumor,
antivirus, antibiosis, immune suppression and so on. Because of the particular
extreme conditions that include high pressure, low temperature, oxygen deficit,
extreme pH value, high salinity, high metallicity, empty illumination, poor nutrition,
high halogen the deep sea microorganisms live in, they have the unique metabolic
pathway and heredity backgrounds and they can produce secondary-metabolites with
novel structures, distinctive functions and slight side-effects. The
secondary-metabolite is one of the most important sources in hunting for novel
anti-tumor drugs. Thus marine fungus usually can generate bioactive metabolites and
the research for these bioactive metabolites is of great significance in seeking for
new drugs.
In this study, Aspergillus versicolor strain from the eastern Pacific about 3000
meters deep sediments was chosen for further research because of its cytotoxicity.
After large scale culture, fermentation, extraction, concentration of Aspergillus
versicolor, 22 compounds were separated by various chromatographic methods, such
as macroporous resin, silica gel, ODS reversed-phase column, HPLC and so on.
In accordance with their physico-chemical properties and data of
NMR(1H-NMR, 13C-NMR), their structures can be judged as: butyl benzoate (1),
(3b,22e)-ergosta-5,7,22-trien-3-ol (2), 5α,8α-ergosta-6,22-diene-3β,5,8-triol (3),
cyclo(Ile-Val) (4), cyclo(Pro-Val) (5), 4-hydroxyphenethyl alcohol (6),
4-hydroxybenzoic acid (7), 3-hydroxybenzoic acid (8), 7,7-bis(3-indolyl)-p-cresol
(9), 3,3-Bis(1H-indol-3-yl)indolin-2-one (10), Secalonic Acid F (11), cyclo(Pro-Tyr)















hydro-chloromycetin (16), cyclo(Trp-Tyr) (17), cyclo(Phe-Tyr) (18), adenosine (19),
Ethyl 5-nitro-1H-indole-2-carboxylate (20), 7-Benzyloxyindole (21),
1,1,2-Trimethyl-1H-benz[e]indole (22). And we have the preliminary study of the
impact of temperature on the secondary metabolites from Aspergillus versicolor. In
vitro activity tests, compound 5, 12, 13, 14 and 15 don’t have cytotoxic activity.
All in all, our study indicated that deep-sea marine microorganism metabolites
were effective resources for compound precursors with structural novelty.
Researching on the secondary metabolites from deep sea microorganism is greatly
meaningful in exploiting marine new resources, seeking for novel anti-tumor drug.

















TLC Thin Layer Chromatography






ESI-MS Electrospray Ionization Mass Spectrometry
FT-MS Fourier Transform Mass Spectroscopy
TOF-MS Time of Llight Mass Spectrometry
TMS Trimethylsiyl
NMR Nuclear Magnetic Resonance
1H-NMR 1H Nuclear Magnetic Resonance
13C-NMR 13C Nuclear Magnetic Resonance
DEPT Distortionless Enhancement By Polarlization Transfer
HSQC 1H -Detected Heteronuclear Sigle Quantum Correlation
HMBC 1H -Detected Heteronuclear Multiple-Bond Correlation
COSY Correlation Spectroscopy
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Name Lead compound Mechanism of action Development
status
aplidin Aplidin VEGF and VEGFR1 inhibitor G1/G2
phase cell cycle inhibitor
phaseⅡ




KRN-7000 agelasphin immunostimulation through ligand
activated Val4 NKT
phase Ⅰ/Ⅱ
discodermolide discodermolide tubulin stabilization phaseⅠ
E-7389 halichondrin B tubulin assembly inhibition phaseⅠ
HTI-286 hemiasterlin tubulin assembly inhibition phaseⅠ
dolastatin-10 dolastatin 10 tubulin assembly inhibition phaseⅡ
soblidotin dolastatin 10 tubulin assembly inhibition phaseⅡ
synthadotin dolastatin 15 tubulin assembly inhibition phaseⅡ
kahalalide F kahalalide F alters lysosomal membrane function phaseⅡ
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